Bayer’s competitor plans to acquire US biotech Ignyta in order to get access to TKR inhibitor.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Roche calls
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
22 Dec 2017 -
Author:
Martin Schnee -
Pages:
2
Bayer’s competitor plans to acquire US biotech Ignyta in order to get access to TKR inhibitor.